31R.F Revive Therapeutics Ltd
- Market cap
- EUR 4.89M
- P/E
- -
- P/B
- 0.12x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.
Is 31R.F undervalued?
Graham numberThe Graham number of Revive Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revive Therapeutics Ltd fundamental analysis
No fundamental analysis for Revive Therapeutics Ltd yet.
Revive Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develop…
Full company profileRevive Therapeutics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Revive Therapeutics Ltd annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.67M | -1.84M | -1.32M | -3.68M | -18.6M | -17.8M | -5.52M | -3.29M | -1.65M | -1.28M |
| EBITDA | -1.67M | -1.84M | -1.34M | -5.27M | -20.0M | -17.7M | -6.28M | -5.60M | -11.0M | -1.37M |
| Net Income | -1.62M | -1.79M | -1.34M | -5.38M | -20.1M | -17.8M | -6.32M | -5.62M | -11.0M | -1.37M |
| EPS | -0.03 | -0.03 | -0.02 | -0.03 | -0.06 | -0.06 | -0.02 | -0.01 | -0.03 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 1.92M | 1.12M | 1.28M | 8.26M | 29.8M | 17.1M | 14.3M | 10.6M | 205K | 282K |
| Total Liabilities | 309K | 299K | 322K | 832K | 1,000K | 4.46M | 3.60M | 3.40M | 3.66M | 4.31M |
| Shareholders' Equity | 1.62M | 821K | 961K | 7.43M | 28.8M | 12.6M | 10.7M | 7.23M | -3.46M | -4.02M |
| Cash & Short-term Investments | 1.77M | 1.06M | 475K | 1.38M | 16.6M | 3.92M | 2.09M | 773K | 14.6K | 12.7K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.08M | -1.50M | -1.18M | -2.52M | -8.31M | -13.1M | -6.03M | -3.29M | -768K | -201K |
| Capital Expenditure | 1.54K | 1.54K | 685.00 | 0.00 | 3.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.08M | -1.51M | -1.19M | -2.52M | -11.3M | -13.1M | -6.03M | -3.29M | -768K | -201K |
| Ratios | ||||||||||
| ROE | -100.0% | -218.1% | -139.9% | -72.4% | -69.8% | -141.3% | -59.3% | -77.7% | - | - |
| ROA | -84.0% | -159.8% | -104.8% | -65.1% | -67.5% | -104.3% | -44.4% | -52.8% | -5,370.8% | -486.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Revive Therapeutics Ltd dividends
Revive Therapeutics Ltd has not paid dividends in the last 9 fiscal years.
Who owns Revive Therapeutics Ltd
- Insiders 1.45%
- Institutions 0.00%
- Public & others 98.55%
- Shares outstanding 445M
- Free float 438M
Revive Therapeutics Ltd company profile
- Company name
- Revive Therapeutics Ltd
- Ticker
- 31R.F
- ISIN
- CA7615161030
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- The Canadian Venture Building, Toronto, ON, Canada, M5C 1P1
- Phone
- 888-901-0036
- Website
- revivethera.com
About Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
Revive Therapeutics Ltd management
4- Mr. Michael FrankChairman & CEO · born 1961
- Mr. Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGAChief Financial Officer · born 1971
- Dr. Kelly T. McKee Jr., M.D., M.P.H.Chief Scientific Officer Consultant · born 1950
- Dr. Onesmo Mpanju Ph.D.Chief Regulatory Affairs Consultant